Pharma
NS Pharma’s Duchenne Muscular Dystrophy Therapy Viltepso Fails Confirmatory Trial
NS Pharma, Viltepso, Duchenne Muscular Dystrophy, Confirmatory Trial, Phase III, RACER53 Study, FDA Approval
NS Pharma’s Viltepso Fails Confirmatory Phase III Trial for Duchenne Muscular Dystrophy Treatment
Viltepso, NS Pharma, Duchenne muscular dystrophy, RACER53 study, viltolarsen, FDA approval, confirmatory trial, phase III trial, DMD treatment
Royalty Pharma Invests $525 Million in Sanofi-Licensed Multiple Sclerosis Therapy Royalties and Milestones
Royalty Pharma, Sanofi, multiple sclerosis therapy, royalties, milestones, investment, healthcare, pharmaceuticals, licensing
Verona Pharma Prepares $650 Million Funding Pool for Ensifentrine Launch Ahead of FDA Decision
Verona Pharma, COPD, Ensifentrine, FDA, funding pool, launch, clinical trials, chronic obstructive pulmonary disease
Optimizing Pharmaceutical Supply Chains: The Evolving Role of Third-Party Logistics Providers
Third-Party Logistics (3PL) Providers, Pharmaceutical Supply Chain, Pharma 4.0, Regulatory Compliance, Cold Chain Management, Data Mining and Management, Licensing Requirements